Prognostic Value of Her2/neu Expression in Gastrointestinal Stromal Tumors: Immunohistochemical Study.

Autor:	Abd El-Aziz AM; Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Ibrahim EA; Department of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Abd-Elmoghny A; Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt., El-Bassiouny M; Department of Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Laban ZM; Columbia University, NY, USA., Saad El-Din SA; Department of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Shohdy Y; Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Jazyk:	angličtina
Zdroj:	Cancer growth and metastasis [Cancer Growth Metastasis] 2017 Feb 16; Vol. 10, pp. 1179064417690543. Date of Electronic Publication: 2017 Feb 16 (Print Publication: 2017).
DOI:	10.1177/1179064417690543
Abstrakt:	Background: Gastrointestinal stromal tumor (GIST) is a relatively rare type of neoplasms. In Egypt, it represents 2.5% of gastrointestinal tumors and 0.3% of all malignancies. Most of the GISTs develop in the stomach. Aim: To reveal the significance of Her2/neu immunohistochemical expression in GIST and its correlation with other histopathologic parameters and tumor relapse after regular follow-up. Patients and Methods: This study is a retrospective and prospective cohort. It included 32 patients with GISTs, who were resectable with no distant metastasis. Immunohistochemical staining by Her2/neu was performed after complete surgical resection of the tumors with preservation of the pseudocapsule. Results: In total, 53.1% of cases were men and 46.9% women. Tumors were classified into low-risk (25%), intermediate-risk (21.9%), and high-risk groups (53.1%). Her2/neu expression was negative in 56.3% of GISTs and positive in 43.7%. Its expression was significantly correlated with risk grade ( P = .04), tumor size ( P = .001), mitotic count ( P = .00), and increased risk of relapse ( P = .00). Furthermore, tumor relapse was significantly correlated with the tumor mitotic counts ( P = .00). Using kappa agreement test, it showed that 4 mitotic counts/50 high-power fields (HPF) was the cutoff value with which the tumor might be associated more with relapse, with 83% sensitivity, 70% specificity, and P value of .003. Conclusions: Her2/neu might be used as an independent prognostic marker for tumor recurrence after complete resection of GIST, and the cutoff value of mitotic count that might predict tumor relapse is 4/50 HPF. However, more clinical studies with greater number of cases with fluorescent in situ hybridization integration are recommended. Competing Interests: DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu